Bayer AG and Johnson & Johnson agreed to pay $775 million to settle more than 25,000 U.S. lawsuits tied to their blood thinner Xarelto, according to Reuters.
The settlement resolves all outstanding U.S. lawsuits over Xarelto. Plaintiffs in the lawsuits claimed the blood thinner causes uncontrollable and irreversible bleeding and said the drugmakers failed to adequately warn of that risk.
Under the settlement agreement, each drugmaker will pay half. Neither company admits wrongdoing under the agreement.
Bayer jointly developed Xarelto in partnership with J&J’s Janssen Pharmaceuticals unit, which sells the blood thinner in the U.S.
Xarelto is Bayer's best-selling drug. In 2018, it generated $4.07 billion in revenue for the company.